The $400 million deal was announced in May 2019. Ethicon and Takeda “mutually decided” to terminate the transaction over regulatory concerns, a Johnson & Johnson representative told Reuters.
The Federal Trade Commission had concluded the deal could have anti-competitive effects because Johnson & Johnson sells another FDA-approved fibrin sealant patch designed to stop intraoperative bleeding.
FTC staff recommended blocking the transaction, chairman Joseph Simons said April 10, the day the deal was called off.
More articles on devices:
21 ASCs with coronavirus restrictions or closures
How gastroenterology practices are responding to COVID-19
How COVID-19 has affected Tenet, HCA Healthcare and Surgery Partners’ shares
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.